fezolinetant + placebo
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Vasomotor Symptoms
Conditions
Vasomotor Symptoms
Trial Timeline
Nov 8, 2021 → Apr 20, 2023
NCT ID
NCT05033886About fezolinetant + placebo
fezolinetant + placebo is a phase 3 stage product being developed by Astellas Pharma for Vasomotor Symptoms. The current trial status is completed. This product is registered under clinical trial identifier NCT05033886. Target conditions include Vasomotor Symptoms.
What happened to similar drugs?
1 of 13 similar drugs in Vasomotor Symptoms were approved
Approved (1) Terminated (0) Active (12)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (12)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06917313 | Phase 2 | Recruiting |
| NCT06812754 | Phase 2 | Completed |
| NCT06206421 | Phase 3 | Active |
| NCT06206408 | Phase 3 | Completed |
| NCT05034042 | Phase 2 | Completed |
| NCT05033886 | Phase 3 | Completed |
| NCT04234204 | Phase 3 | Completed |
| NCT04003155 | Phase 3 | Completed |
| NCT04003142 | Phase 3 | Completed |
| NCT04003389 | Phase 3 | Completed |
| NCT03192176 | Phase 2 | Completed |
| NCT05419908 | Phase 2 | Completed |
Competing Products
20 competing products in Vasomotor Symptoms